Brind.
  1. The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs.
  2. ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.

ImmunityBio met with the FDA division on August 5, 2025, to present data regarding its ANKTIVA drug used in an NCI cancer prevention trial.

1 report, 1 independent Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

ImmunityBio met with the FDA division on August 5, 2025, to present data regarding its ANKTIVA drug used in an NCI cancer prevention trial.

Who's involved

What this event is mainly about
ImmunityBioFDA

Keep exploring

Part of

ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston. All 1 developments

Within The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs.

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code Q2 2025 Revenue Growth with Continued S